Question explored with the scientific record
Can astra zeneca shed
The short version: the AstraZeneca vaccine is a replication-defective adenovirus vector, so it cannot replicate and shed like a live virus, but the spike protein it produces can be shed from cells and has been detected in blood and tissues, which is a different kind of shedding with its own risks.
The AstraZeneca vaccine uses a chimpanzee adenovirus (ChAdOx1) that has been engineered so it cannot replicate [6]. That means it cannot produce infectious virus particles that you could cough or sneeze onto someone else. This is fundamentally different from live-attenuated vaccines like the measles or flu nasal spray, which do shed replicating virus. The evidence you retrieved does not contain a single study testing whether the AstraZeneca vaccine sheds replication-competent virus from vaccinated people, and no study in this set found transmission of the vaccine virus to others.
But the question of shedding does not end there. The vaccine delivers DNA that instructs your cells to produce the spike protein. That spike protein itself can be shed from cells into the bloodstream and tissues. Multiple studies in this retrieval document that the spike protein produced by the vaccine triggers a strong innate immune response [7, 8, 9], and the adenovirus vector itself is detected by cellular DNA sensors like cGAS-STING [8] and AIM2/NALP3 [7], which drive inflammation. The spike protein has been linked to blood-clotting disorders through its interaction with platelet factor 4 [6], and the vaccine has been associated with serious thrombotic events including cerebral venous sinus thrombosis and portal vein thrombosis [3, 4, 5]. These are not shedding in the infectious sense, but they represent a form of biological shedding of the vaccine's active components into the body.
The evidence also shows the vaccine can reactivate latent viruses. One case report documents herpes zoster (shingles) after a single AstraZeneca dose [2], and another describes a patient who developed Guillain-Barre syndrome after the second dose [1]. These are not shedding of the vaccine itself, but they are consequences of immune perturbation that the vaccine causes.
My call: the AstraZeneca vaccine does not shed replication-competent virus in the traditional sense, but the spike protein it produces is shed from cells into the body, and the vaccine triggers inflammatory and autoimmune responses that can cause harm. Confidence: high on the replication-defective mechanism, moderate on the clinical significance of spike protein shedding.
Sources used 9
-
A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination
This case report describes a 68-year-old woman who developed Guillain-Barre syndrome characterized by acute inflammatory demyelinating polyradiculoneuropathy after receiving the second dose of the AstraZeneca COVID-19 vaccine.
DOI: 10.5606/tftrd.2022.9984 -
Zoster infection after vaccination with the AstraZeneca COVID-19 vaccine: A case report
A 55-year-old man developed herpes zoster after a single AstraZeneca COVID-19 vaccine dose; the lesion resolved without residual neuralgia, and the authors suggest immunity after one dose may wane rapidly.
DOI: 10.7241/ourd.20221.9 -
Portal Vein Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) after Covid Vaccination with ChAdOx1 nCoV-19
This case report describes a 29-year-old male who developed portal vein thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (VITT) following vaccination with the AstraZeneca COVID-19 vaccine, highlighting the importance of early diagnosis and treatment.
DOI: 10.1055/a-1579-9303 -
Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure
This study describes three cases of women who developed thrombocytopenia and intracranial venous sinus thrombosis following vaccination with the COVID-19 vaccine AstraZeneca, highlighting the clinical manifestations, laboratory findings, and treatment outcomes.
DOI: 10.3390/jcm10081599 -
Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19
This study reports a case of cerebral venous sinus thrombosis associated with thrombocytopenia in a previously healthy 50-year-old man following vaccination with the AstraZeneca COVID-19 vaccine, highlighting the potential risks of thromboembolic events post-vaccination.
DOI: 10.1186/s13054-021-03572-y -
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
This study compares the ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vaccines, revealing significant differences in their composition and functional properties that may contribute to the varying incidence rates of vaccine-induced thrombosis with thrombocytopenia syndrome (VITT/TTS…
DOI: 10.3324/haematol.2021.280154 -
Innate immune response after adenoviral gene delivery into skin is mediated by AIM2, NALP3, DAI and mda5
Keratinocytes detect cytosolic adenoviral DNA and mount an innate immune response via AIM2, NALP3, DAI and mda5, reducing transgene expression upon vector reapplication and highlighting receptor pathways that shape skin gene delivery.
DOI: 10.1186/2193-1801-2-234 -
Adenovirus Detection by the cGAS/STING/TBK1 DNA Sensing Cascade
This study demonstrates that the cytosolic DNA sensor cGAS, signaling through STING and TBK1, is the dominant mechanism for detecting adenovirus in murine endothelial and macrophage cells, and that knockdown of cGAS impairs both primary IRF3 activation and downstream antiviral g…
DOI: 10.1128/jvi.02702-13 -
The Role of Endosomal Escape and Mitogen-Activated Protein Kinases in Adenoviral Activation of the Innate Immune Response
In a mouse model, the authors show that endosomal escape is required for adenovirus-induced activation of ERK and p38 MAPKs, but inhibition of these MAPK pathways only modestly affects the broad innate cytokine/chemokine response, indicating redundancy in Adenovirus sensing and …
DOI: 10.1371/journal.pone.0026755